Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Structure activity relationships of fused bicyclic and urea derivatives of spirocyclic compounds as potent CCR1 antagonists.

Hossain N, Mensonides-Harsema M, Cooper ME, Eriksson T, Ivanova S, Bergström L.

Bioorg Med Chem Lett. 2014 Jan 1;24(1):108-12. doi: 10.1016/j.bmcl.2013.11.062. Epub 2013 Dec 4.

PMID:
24332486
2.

Design, synthesis and structure activity relationships of spirocyclic compounds as potent CCR1 antagonists.

Hossain N, Ivanova S, Bergare J, Mensonides-Harsema M, Cooper ME.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3500-4. doi: 10.1016/j.bmcl.2013.04.047. Epub 2013 Apr 28.

PMID:
23659855
3.

Design, synthesis and structure-activity relationships of zwitterionic spirocyclic compounds as potent CCR1 antagonists.

Hossain N, Ivanova S, Timén ÅS, Bergare J, Mussie T, Bergström L.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4026-30. doi: 10.1016/j.bmcl.2013.05.087. Epub 2013 Jun 6.

PMID:
23769642
4.

Spirocyclic compounds, potent CCR1 antagonists.

Hossain N, Ivanova S, Bergare J, Eriksson T.

Bioorg Med Chem Lett. 2013 Mar 15;23(6):1883-6. doi: 10.1016/j.bmcl.2012.12.095. Epub 2013 Jan 23.

PMID:
23414842
5.

The discovery of BMS-457, a potent and selective CCR1 antagonist.

Gardner DS, Santella JB 3rd, Duncia JV, Carter PH, Dhar TG, Wu H, Guo W, Cavallaro C, Van Kirk K, Yarde M, Briceno SW, Grafstrom RR, Liu R, Patel SR, Tebben AJ, Camac D, Khan J, Watson A, Yang G, Rose A, Foster WR, Cvijic ME, Davies P, Hynes J Jr.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3833-40. doi: 10.1016/j.bmcl.2013.04.079. Epub 2013 May 7.

PMID:
23707259
6.

Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase.

Keith JM, Jones WM, Pierce JM, Seierstad M, Palmer JA, Webb M, Karbarz MJ, Scott BP, Wilson SJ, Luo L, Wennerholm ML, Chang L, Brown SM, Rizzolio M, Rynberg R, Chaplan SR, Breitenbucher JG.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):737-41. doi: 10.1016/j.bmcl.2013.12.113. Epub 2014 Jan 6.

PMID:
24433863
7.

AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653.

Norman P.

Expert Opin Ther Pat. 2009 Nov;19(11):1629-33. doi: 10.1517/13543770903118996.

PMID:
19586423
8.

Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor.

Fichtner M, Lee E, Tomlinson E, Scott D, Cornelius P, Patterson TA, Carpino PA.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2738-43. doi: 10.1016/j.bmcl.2012.02.098. Epub 2012 Mar 6.

PMID:
22445286
9.

Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.

Gilchrist A, Gauntner TD, Fazzini A, Alley KM, Pyen DS, Ahn J, Ha SJ, Willett A, Sansom SE, Yarfi JL, Bachovchin KA, Mazzoni MR, Merritt JR.

Br J Pharmacol. 2014 Nov;171(22):5127-38. doi: 10.1111/bph.12835.

10.

Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists.

Merritt JR, Liu J, Quadros E, Morris ML, Liu R, Zhang R, Jacob B, Postelnek J, Hicks CM, Chen W, Kimble EF, Rogers WL, O'Brien L, White N, Desai H, Bansal S, King G, Ohlmeyer MJ, Appell KC, Webb ML.

J Med Chem. 2009 Mar 12;52(5):1295-301. doi: 10.1021/jm801416q.

PMID:
19183043
11.

Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2).

Strunz AK, Zweemer AJ, Weiss C, Schepmann D, Junker A, Heitman LH, Koch M, Wünsch B.

Bioorg Med Chem. 2015 Jul 15;23(14):4034-49. doi: 10.1016/j.bmc.2015.02.019. Epub 2015 Feb 18.

PMID:
25766632
12.

Novel skeleton transformation reaction of α-pyrone derivatives to spirobicyclo[3.1.0]hexane derivatives using dimethylsulfoxonium methylide.

Miura T, Yadav ND, Iwasaki H, Ozeki M, Kojima N, Yamashita M.

Org Lett. 2012 Dec 7;14(23):6048-51. doi: 10.1021/ol302942m. Epub 2012 Nov 19.

PMID:
23163935
13.

Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor.

Chaturvedula PV, Pin S, Tholady G, Conway CM, Macor JE, Dubowchik GM.

Bioorg Med Chem Lett. 2012 Jul 15;22(14):4719-22. doi: 10.1016/j.bmcl.2012.05.118. Epub 2012 Jun 9.

PMID:
22732695
14.

Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds.

Sakamoto T, Moriya M, Tsuge H, Takahashi T, Haga Y, Nonoshita K, Okamoto O, Takahashi H, Sakuraba A, Hirohashi T, Shibata T, Kanno T, Ito J, Iwaasa H, Gomori A, Ishihara A, Fukuroda T, Kanatani A, Fukami T.

Bioorg Med Chem. 2009 Jul 15;17(14):5015-26. doi: 10.1016/j.bmc.2009.05.064. Epub 2009 Jun 2.

PMID:
19525116
15.

Pd-catalyzed enantioselective intramolecular α-arylation of α-substituted cyclic ketones: facile synthesis of functionalized chiral spirobicycles.

Fan L, Takizawa S, Takeuchi Y, Takenaka K, Sasai H.

Org Biomol Chem. 2015 May 7;13(17):4837-40. doi: 10.1039/c5ob00382b.

PMID:
25806855
16.

Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists II: lead optimization.

Alonso JA, Andrés M, Bravo M, Calbet M, Eastwood PR, Eichhorn P, Esteve C, Ferrer M, Gómez E, González J, Mir M, Moreno I, Petit S, Roberts RS, Sevilla S, Vidal B, Vidal L, Vilaseca P, Zanuy M.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):5123-6. doi: 10.1016/j.bmcl.2014.08.029. Epub 2014 Aug 19.

PMID:
25437505
17.

Design and synthesis of novel opioid ligands with an azabicyclo[2.2.2]octane skeleton and their pharmacologies.

Watanabe Y, Kitazawa S, Fujii H, Nemoto T, Hirayama S, Nagase H.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2689-92. doi: 10.1016/j.bmcl.2012.03.001. Epub 2012 Mar 8.

PMID:
22445285
18.

Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.

Santella JB 3rd, Gardner DS, Duncia JV, Wu H, Dhar M, Cavallaro C, Tebben AJ, Carter PH, Barrish JC, Yarde M, Briceno SW, Cvijic ME, Grafstrom RR, Liu R, Patel SR, Watson AJ, Yang G, Rose AV, Vickery RD, Caceres-Cortes J, Caporuscio C, Camac DM, Khan JA, An Y, Foster WR, Davies P, Hynes J Jr.

J Med Chem. 2014 Sep 25;57(18):7550-64. doi: 10.1021/jm5003167. Epub 2014 Sep 3.

PMID:
25101488
19.

2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis.

Shukla L, Ajram LA, Begg M, Evans B, Graves RH, Hodgson ST, Lynn SM, Miah AH, Percy JM, Procopiou PA, Richards SA, Slack RJ.

Eur J Med Chem. 2016 Jun 10;115:14-25. doi: 10.1016/j.ejmech.2016.02.058. Epub 2016 Feb 27.

PMID:
26991939
20.

Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.

Takahashi T, Haga Y, Sakamoto T, Moriya M, Okamoto O, Nonoshita K, Shibata T, Suga T, Takahashi H, Hirohashi T, Sakuraba A, Gomori A, Iwaasa H, Ohe T, Ishihara A, Ishii Y, Kanatani A, Fukami T.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3511-6. doi: 10.1016/j.bmcl.2009.05.013. Epub 2009 May 9.

PMID:
19464889

Supplemental Content

Support Center